Cancer Patients Europe (CPE) welcomes the opportunity to comment on the European Commission's proposal to amend Regulation (EU) 2017/745 on medical devices (MDR) and Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR). Medical devices and in vitro diagnostics are essential throughout the cancer pathway, from screening and diagnosis to treatment and follow-up.
CPE
Cancer Patients Europe (CPE)
NGO · Belgium · EU Transparency Register 476628448625-07
9
positions filed
in the 665 files tracked
6
legislative files
of 665 tracked
2
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 665 consultation files tracked so far (57,774 submissions, mostly 2021–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 1106 non-governmental organisations on this site, they rank #204 by legislative files engaged, a count of participation, not a measure of influence.
3.8
declared lobbying FTE
self-declared
–
declared costs / yr (floor)
5
EP accreditations
as declared to the register
2023
in the register since
Declares membership of
- CPE Alliances:
- EMIH –European Microbiome Innovation for Health
- OnHOME Alliance
- Cancer Prevention Europe
- Coalition Against Nitrities
- EEA - European Access Academy
- BBMRI-ERIC - Biobanking and Biomolecular Resources Research Infrastructure – European Research Infrastructure Consortium
- EU-X-CT Initiative
- World Ovarian Cancer Coalition
- CPE Collaborations
- ESMO
- EHA – European Hematology Association
- and 17 more
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026).
- Register category
- Non-governmental organisations
- Registered as
- Cancer Patients Europe (CPE)
- Head office
- Brussels, Belgium
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track Cancer in PolicySpeak: request access →
Work at Cancer Patients Europe (CPE)? so we know who speaks for it.
Their record over time
Cancer Patients Europe (CPE) filed 9 positions between 11 Jun 2025 and 31 Jul 2026, across 6 of the 665 legislative files tracked here, attaching a full position paper 2 times.
2025 · 3 filed2026 · 6 filed
What they argued
Cancer Patients Europe (CPE) response to the European Commissions Call for Evidence on the targeted revision of EU rules for medical devices and in vitro diagnostics (MDR/IVDR) Cancer Patients Europe (CPE) welcomes the opportunity to contribute to the targeted revision of Regulation (EU) 2017/745 on medical devices (MDR) and Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR).
Cancer Patients Europe (CPE) welcomes the European Commissions proposal for the next Multiannual Financial Framework (MFF) and its ambition to create a more strategic, simplified and forward-looking EU budget. We recognise that the proposed European Competitiveness Fund (ECF), as well as the National and Regional Partnership Plans and the Preparedness and Crisis Mechanism, represent an effort to strengthen the…
Cancer Patients Europe (CPE) welcomes the European Commission's proposal for a European Biotech Act and supports its ambition to strengthen Europe's biotechnology and biomanufacturing ecosystem. Biotechnology has enormous potential to improve disease prevention, diagnosis and treatment, particularly through advanced diagnostics, innovative therapies and clinical research.
Cancer Patients Europe (CPE) response to the European Commission consultation on the proposed Directive accompanying the European Biotech Act CPE welcomes the European Commission's proposed Directive amending Directives 2001/18/EC and 2010/53/EU as part of the implementation of the European Biotech Act.
Cancer Patients Europe (CPE) welcomes the opportunity to contribute to the European Commissions call for evidence on the proposed Biotech Act. We fully support its aim to establish a robust, forward-looking policy framework to strengthen Europes leadership in biotechnology, particularly in healthcare.
Cancer Patients Europe (CPE) response to the Consultation on the Commission Implementing Regulation on the EHDS Board Cancer Patients Europe (CPE) welcomes the draft Commission Implementing Regulation establishing the European Health Data Space (EHDS) Board.
Cancer Patients Europe (CPE) welcomes the draft Commission Implementing Regulation on MyHealth@EU adopted under Article 23(4) and (8) of Regulation (EU) 2025/327, and supports its objective of enabling secure, interoperable cross-border exchange of personal electronic health data under the European Health Data Space.
Cancer Patients Europe (CPE) welcomes the draft Commission Implementing Regulation on an interoperable, cross-border identification and authentication mechanism for natural persons, health professionals and healthcare providers for the cross-border exchange of personal electronic health data. While CPE supports its objectives, we highlight some implementation considerations from a patient perspective.
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Put Cancer Patients Europe (CPE) next to another organization. Same files, same register facts, side by side. Compare →
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers, not evidence of coordination, and we do not suggest any.
Showing 5 of 86.
Is this your organization?
Everything on this page comes from Cancer Patients Europe (CPE)’s own submissions to the European Commission. We have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.